Module 1: Ibrutinib for Hematologic Malignancies_Matthew Davids, MD, MMSc_Catherine Coombs_MD_Anthony Mato, MD, MSCE
9:28
Chronic Lymphocytic Leukemia
Module 1: Ibrutinib for Hematologic Malignancies_Matthew Davids, MD, MMSc_Catherine Coombs_MD_Anthony Mato, MD, MSCE
Chronic Lymphocytic Leukemia Similar Videos
Similar Videos
-
Module 5: Experts Debate Optimal Selection and Sequencing Strategies_Matthew Davids, MD, MMSc_Catherine Coombs, MD_Anthony Mato, MD, MSCE
21:45
-
Module 4: Emerging BTK Inhibitors_Matthew Davids, MD, MMSc_Catherine Coombs, MD_Anthony Mato, MD, MSCE
12:02
-
Module 3: Zanubrutinib for Hematologic Malignancies_Matthew Davids, MD, MMSc_Catherine Coombs, Anthony Mato, MD, MSCE
7:59